sardomozide (SAM486) / Novartis - LARVOL DELTA

Cysteine Restriction Induces Ferroptosis Depending on the S-adenosylmethionine and Polyamine Biosynthetic Pathways in Hepatic Cancer Cells. (PubMed, Gastro Hep Adv) - "Inhibitors of ferroptosis (Fer-1), necroptosis (GSK872), SAM synthesis (cycloleucine), or polyamine synthesis (sardomozide and difluoromethylornithine) were used...These results suggest that cysteine-glutathione and SAM-polyamine metabolic pathways are critical modulators of ferroptosis of hepatic cancer cells. Since normal liver cells were more resistant to ferroptosis than cancer cells, cysteine restriction may be exploited in treating hepatic cancer by inducing ferroptosis specifically in cancer cells without affecting normal cells in the liver."

Journal • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • ANXA5 • MAT2A

The Polyamine Inhibitor SAM486 Increases Adagrasib Efficacy in Non-Small Cell Lung Cancer Cells Bearing G12C Mutation (LALCA 2024) - No abstract available

Clinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Synergistic enhancement of KRASG12C inhibitor adagrasib by AMD1 inhibitor SAM486 in non-small cell lung cancer: in vitro and in vivo studies (EORTC-NCI-AACR 2024) - "These findings suggest that the combination of the KRASG12C inhibitor adagrasib and the AMD1 inhibitor SAM486 could provide a novel and synergistic therapeutic strategy against tumors with KRASG12C mutations."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS • PCNA

Polyamine Inhibitor SAM486A Augments Cytarabine Cytotoxicity in Methylthioadenosine Phosphorylase-deficient Leukemia Cells. (PubMed, Anticancer Res) - "Methionine metabolism and polyamine synthesis can be attractive therapeutic targets in leukemia."

Journal • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • MTAP